Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells

International Journal of Biochemistry and Molecular Biology

Volumn 1, Issue 1, 2010, Pages 90-100

  Park, Soo Jung ^a,b,c   Bijangi Vishehsaraei, Khadijeh ^a,b   Safa, Ahmad R ^a,b  

^a Department of Pharmacology and Toxicology ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c National Masan Hospital   (South Korea)

Author keywords

Apoptosis; Caspases; Death receptors; P glycoprotein; TRAIL; TRAIL death receptor 5 (DR5)

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CYTOCHROME C; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LIPOCORTIN 5; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VINBLASTINE; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRION; MULTIDRUG RESISTANCE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; RECEPTOR UPREGULATION; RNA ISOLATION;

EID: 79952173594     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res. 2010; 34(7):837-42.
2. Clarke R, Leonessa F, Trock B. Multidrug resistance/ P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol. 2005; 32(6 Suppl 7):S9-15.
3. Türk D, Szakács G. Relevance of multidrug resistance in the age of targeted therapy. Curr Opin Drug Discov Devel. 2009; 12(2):246-52.
4. Glavinas, H., Krajcsi, P., Cserepes, J., Sarkadi, B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 2004; 1(1) 27-42.
5. Roberti A, La Sala D, Cinti C. Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol. 2006; 207 (3) 571-81.
6. Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets. 2008; 8 (1):37-46.
7. Zhong X, Safa AR. Phosphorylation of RNA helicase A by DNA-dependent protein kinase is indispensable for expression of the MDR1 gene product P-glycoprotein in multidrug-resistant human leukemia cells. Biochemistry. 2007; 46 (19):5766-75.
8. Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem. 2010; 17(8):786-800.
9. Schulze-Bergkamen H, Krammer PH. Apoptosis in cancer--implications for therapy. Semin Oncol. 2004; 31(1):90-119.
10. Zivny J, Klener P Jr, Pytlik R, Andera L. The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des. 2010; 16(1):11-33.
11. Del Poeta G, Bruno A, Del Principe MI, Venditti A, Maurillo L, Buccisano F, Stasi R, Neri B, Luciano F, Siniscalchi A, de Fabritiis P, Amadori S. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets. 2008; 8(3):207-22.
12. Tan TT, White E. Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv Exp Med Biol. 2008; 615:81-104.
13. Is TRAIL the holy grail of cancer therapy? Newsom-Davis T, Prieske S, Walczak H. Apoptosis 2009; 14(4): 607-23.
14. Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res. 2010; 316(6): 887-99.
15. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009; 48(6):811-21.
16. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2(6):420-30.
17. Day TW, Huang S, Safa AR. c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol. 2008; 76(12):1694-704.
18. Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta. 2010; 1805 (2):123-40.
19. Muppidi JR, Lobito AA, Ramaswamy M, Yang JK, Wang L, Wu H, Siegel RM. Homotypic FADD interactions through a conserved RXDLL motif are required for death receptor-induced apoptosis. Cell Death Differ. 2006; 13(10):1641-50.
20. Collison A, Foster PS, Mattes J.Emerging role of tumour necrosis factor-related apoptosisinducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol. 2009; 36(11):1049-53.
21. Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis. 2007; 12(9):1623-32.
22. Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR. P-glycoprotein enhances TRAILtriggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol. 2006; 72(3):293-307.
23. Wu CH, Kao CH, Safa AR. TRAIL recombinant adenovirus triggers robust apoptosis in multidrug- resistant HL-60/Vinc cells preferentially through death receptor DR5. Hum Gene Ther. 2008; 19(7): 731-43.
24. Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem. 2009; 108(1):106-16.
25. Frese-Schaper M, Schardt JA, Sakai T, Carboni GL, Schmid RA, Frese S. Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett. 2010; 584(13):2867-71.
26. Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, Schneider G. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer. 2010; 9:80.
27. Pellerito O, Calvaruso G, Portanova P, De Blasio A, Santulli A, Vento R, Tesoriere G, Giuliano M. The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis by activating p8/ CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. Mol Pharmacol. 2010; 77(5):854-63.
28. Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY. CAAT/ enhancer binding protein homologous proteindependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008; 68(13):5335-44.
29. Lu M, Xia L, Hua H, Jing Y. Acetyl-keto-betaboswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer Res. 2008; 68(4):1180-86.
30. Singh TR, Shankar S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis- inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 2003; 63(17):5390-400.
31. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/type II model. Semin Immunol. 2003; 15 (3):185-93.
32. Wilson TR, McEwan M, McLaughlin K, Le Cloren nec C, Allen WL, Fennell DA, Johnston PG, Longley DB. Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene. 2009; 28 (1):63-72.
33. Maas C, Verbrugge I, de Vries E, Savich G, van de Kooij LW, Tait SW, Borst J. Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation. Cell Death Differ. 2010 Apr 16. [Epub ahead of print]
34. Pradelli LA, Bénéteau M, Ricci JE Mitochondrial control of caspase-dependent and independent cell death. Cell Mol Life Sci. 2010; 67(10):1589-97.
35. Caroppi P, Sinibaldi F, Fiorucci L, Santucci R. Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome c as proapoptotic protein. Curr Med Chem. 2009; 16(31):4058-65.
36. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I doseescalation study of recombinant human Apo2L/ TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28(17):2839-46.